SEMA7A and rheumatoid arthritis: A significant reduction in serum sSema7A levels after biologic DMARD treatment was observed (mean ± SD 12.6 ± 4.3 ng/ml versus 6.7 ± 2.6 ng/ml; P < 0.01) in patients who were good responders according to the European League Against Rheumatism response criteria [28] (Fig. 1c), suggesting the involvement of Sema7A in determining the clinical status of RA.